Appointment dossier — Leiomyosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Leiomyosarcoma
- Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT03016819 · Phase 3 — Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (United States)
- NCT06849986 · Phase 2 — IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) (China)
- NCT06638931 · Phase 2 — Agnostic Therapy in Rare Solid Tumors (Brazil)
- NCT04535271 · Phase 2 — Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma (United States)
- NCT06571734 · Phase 2 — XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma (United States)
- NCT06277154 · Phase 2 — MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (China)
- NCT07125183 · Phase 2 — Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma (United States)
- NCT06524583 · Phase 2 — Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (France)
- NCT06498648 · Phase 1 / Phase 2 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (United States)
- NCT06975293 · Phase 1 / Phase 2 — STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas (United States)
- NCT07173972 · Phase 2 — Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (Norway)
- NCT04383119 · Phase 2 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (Italy)
- NCT07169344 · Phase 2 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (Norway)
- NCT05711615 · Phase 1 — Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (United States)
- NCT05227326 · Phase 1 — AOH1996 for the Treatment of Refractory Solid Tumors (United States)
- NCT07628634 · Early Phase 1 — Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors (United States)
- NCT07432932 — Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients (United Kingdom)
- NCT04055220 — Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (France)
Most-relevant first: trials that name Leiomyosarcoma, then broader trials you may still qualify for. 37 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Trastuzumab Deruxtecan has been studied in people for Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab-Deruxtecan (T-Dxd) has been studied in people for Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT03016819), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?